Monopar Therapeutics Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| Wellington | fundamental | 174.3K | $9.55M | 0.00% | Trimmed-22.9% | 2026-03-31 |
| StateStreet | passive | 88.4K | $4.84M | 0.00% | Added+5.2% | 2026-03-31 |
| TwoSigma | quant | 9.8K | $535.02K | 0.00% | Added+95.7% | 2026-03-31 |
| FidelityFMR | fundamental | 409 | $22.41K | 0.00% | Added+14.2% | 2026-03-31 |
| TRowePrice | fundamental | 47.7K | $2.61K | 0.00% | Added+109.9% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -0.66 | — | — |
| 2026-05-14 | -0.90 | -0.46 | +48.75% |
| 2026-03-27 | -0.51 | -0.61 | -19.08% |
| 2025-11-13 | -0.40 | -0.48 | -20.33% |
| 2025-08-12 | -0.48 | -0.35 | +27.59% |
| 2025-05-13 | -0.57 | -0.38 | +32.94% |
| 2025-03-31 | -0.42 | -2.75 | -554.76% |
| 2024-11-08 | -1.17 | -1.85 | -58.12% |
| 2024-08-09 | -0.47 | -0.50 | -7.14% |
| 2024-05-09 | -0.85 | -0.50 | +41.18% |
| 2024-03-28 | -0.85 | -0.60 | +29.41% |
| 2023-11-09 | -0.95 | -0.70 | +26.32% |
| 2023-08-10 | -0.95 | -0.80 | +15.79% |
| 2023-05-11 | -1.08 | -0.95 | +12.31% |
| 2023-03-23 | -1.02 | -1.15 | -12.20% |
| 2022-11-10 | -1.07 | -0.95 | +11.63% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| MNPR | +22.14% | +25.37% | -0.40% | +104.98% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +19.17% | +30.00% | +3.04% | +92.29% |